Illuminare Biotechnologies’ Rizedisben Demonstrates Safety and Efficacy in Phase 1 Clinical Trial Results
Illuminare Biotechnologies, a company focused on developing a nerve imaging agent to enhance surgical safety, announced first-in-human data results from a Phase 1 clinical trial evaluating Illuminare-1 (rizedisben) in robotic prostate cancer surgeries. The results have been published in JAMA Surgery.
